Logo image
IRO Home Research units Researcher Profiles
Sign in
Intravitreal bevacizumab for treatment of proliferative and nonproliferative type 2 idiopathic macular telangiectasia
Journal article   Peer reviewed

Intravitreal bevacizumab for treatment of proliferative and nonproliferative type 2 idiopathic macular telangiectasia

A Brock Roller, James C Folk, Narendra M Patel, H Culver Boldt, Stephen R Russell, Michael D Abramoff and Vinit B Mahajan
Retina (Philadelphia, Pa.), Vol.31(9), pp.1848-1855
10/2011
DOI: 10.1097/IAE.0b013e31820d3feb
PMID: 21610563

View Online

Abstract

Follow-Up Studies Intravitreal Injections Tomography, Optical Coherence Humans Middle Aged Retinal Telangiectasis - classification Male Treatment Outcome Vascular Endothelial Growth Factor A - antagonists & inhibitors Retinal Telangiectasis - drug therapy Retinal Neovascularization - classification Bevacizumab Retinal Telangiectasis - physiopathology Angiogenesis Inhibitors - administration & dosage Antibodies, Monoclonal, Humanized - administration & dosage Adult Female Aged Retrospective Studies Retinal Neovascularization - drug therapy Retinal Neovascularization - physiopathology Retina - pathology Visual Acuity - physiology Fluorescein Angiography

Details

Logo image